Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy

INTRODUCTION: We present certolizumab pegol (CZP) efficacy data across patient demographic and baseline disease characteristic subgroups from a phase 2/3 trial investigating CZP treatment in Japanese patients with moderate to severe plaque psoriasis (PSO; ClinicalTrials.gov identifier: NCT03051217)....

Descripción completa

Detalles Bibliográficos
Autores principales: Imafuku, Shinichi, Tada, Yayoi, Umezawa, Yoshinori, Sakurai, Shinya, Hoshii, Naoki, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776960/
https://www.ncbi.nlm.nih.gov/pubmed/34826124
http://dx.doi.org/10.1007/s13555-021-00645-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776960/
https://www.ncbi.nlm.nih.gov/pubmed/34826124
http://dx.doi.org/10.1007/s13555-021-00645-2

Ejemplares similares